Hodgkin's lymphoma: Results of ABVD chemotherapy in 40 patients with advanced or bulky disease

Beatrice Uziely, Ruth Isacson, Zeev Weshler, Gilles Lugassy, Eugene Libson, Aaron Polliack

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

During 1980-1986, 40 patients with advanced Hodgkin's disease or bulky disease were treated with six cycles of ABVD chemotherapy, and adjuvant radiotherapy was added to sites of bulky disease when required. Twenty-seven of the 40 patients (67.5%) were treated with ABVD as primary therapy and 13 (32.5%) received it as salvage therapy after initial failure. Twenty-seven patients (67.5%) had advanced stages 3 or 4 disease, while 13 (32.5%) had stage 2 with bulky mediastinal disease (more than 30% chest diameter). Only 7.5 % of the patients had no response to ABVD while 75% achieved CR and 17.5% PR. Seventy-four per cent of the patients with advanced stages 3 and 4 achieved CR and 15% reached PR, with only two failures to ABVD. The median survival for the entire group is currently more than 41 months, with a median disease-free interval (DFI) of 27.5 months for all treated patients. The results compare favorably with those reported from other major centers dealing with larger series of patients. New approaches for future treatment employing alternating shorter courses of MOPP/ABV are discussed, and the importance of radiotherapy for bulky disease is emphasized.

Original languageEnglish
Pages (from-to)123-127
Number of pages5
JournalLeukemia and Lymphoma
Volume1
Issue number2
DOIs
StatePublished - 1 Jan 1990
Externally publishedYes

Keywords

  • ABVD
  • Hodgkin's disease
  • Lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Hodgkin's lymphoma: Results of ABVD chemotherapy in 40 patients with advanced or bulky disease'. Together they form a unique fingerprint.

Cite this